Company Overview and News
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
UNITED STATES SECUR
PHILADELPHIA and OXFORD, United Kingdom, June 11, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that data from the pilot study of NY-ESO SPEAR T‑cells in synovial sarcoma will be published in Cancer Discovery (an American Association of Cancer Research [AACR] publication). Beyond the clinical data, some of which having been reported previously (most recently at CTOS 2017 [https://bit.
ADAP GSK GSK
PHILADELPHIA and OXFORD, United Kingdom, June 02, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented initial data from the ongoing pilot study of NY-ESO SPEAR T-cells in myxoid/round cell liposarcoma (MRCLS). With eight patients treated, the best overall responses include three confirmed partial responses, one unconfirmed partial response, three stable disease, and one recently treated patient awaiting assessment.
ADAP GSK GSK
The market is becoming more comfortable with risk as evidenced by the rise of the small cap index to a new all-time high.
ECYT AVXS GTHX LOXO ARNA ATRA IMMU BIIB CELG HRTX ADAP REGN AMGN GILD NBIX CRSP SRPT ARIA SUPN SNY CBIO JNJ MRTX NVS BGNE IRR CLSD PFE
PHILADELPHIA and OXFORD, U.K., May 16, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will release updated data from ongoing clinical studies at the annual ASCO meeting at McCormick Place in Chicago, Illinois.
ADAP GSK GSK
Bristol-Myers Squibb: "Bristol-Myers right now does not have what we're looking for in terms of that cancer franchise that's going to Merck. I've got to tell you, down here, with a 3 percent yield, it gets attractive. But because of interest rates going higher, I'm going to have to take a pass for the moment."
CKRGZ AEP.PRA ADAP CHKVP LB CHKDH CHKVZ IEP SE CHKDG CHKWZ CHKDJ CHKDP CHK.WI CHK AEP CHK.PRD ED
2018-07-13 - Asif
Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...
2018-07-09 - Asif
Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...
2018-07-06 - Asif
Overview Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company's proprietary paresthesia-free HF10TM therapy, delivered by its Senza system, was demonstrated in its SENZA-RCT study to be superior to traditional SCS therapy with it being nearly twice as successful in treating back pain and 1.5 times as successful in treating leg pain when compared to traditional SCS therapy. Comparatively, traditional SCS therapy has limited efficacy in treating back pain and is used primarily for treating leg pain, limiting its market adoption. The company's SENZA-RCT study, along with its European studies, represents what the company believe is the most robust body of clinical evidence for any SCS therapy. The compa...
Silicon Investor Message Boards
This table lists all message boards related to ADAP / Adaptimmune Therapeutics plc on message board site Silicon Investor.
|Adaptive Broadband (NASDAQ:ADAP)||Adaptec (ADPT)|
|Impinj: SelfAdaptive Semiconductor||SectorTalk - Wireless Broadband - MMDS, Satellite, LMDS|
|IOMC: The Next Adaptec?||ADAP Board|
as of ET